

For Immediate Release



ASX Announcement

18 August, 2026
Melbourne, Australia

Results Presentation for the full year ended 30 June 2026

CSL Limited (ASX:CSL; USOTC:CSLLY)

Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and Chief Financial Officer shortly. The live briefing will be webcast and can be viewed at <https://edge.media-server.com/mmc/p/uhc246xu/>

Please note that this link will expire after the webcast concludes.

A recording of the webcast will be made available later in the day at:
<https://investors.csl.com/investors/financial-results-and-information>

Authorised for lodgement by:

Fiona Mead
Company Secretary



Investor Relations

Michelle Rees
Head, Investor Relations
CSL Limited
P: +61 410 600 745
E: michelle.rees@csl.com.au



Media Relations

Brett Foley
Communications
CSL Limited
P: +61 461 464 708
E: media@csl.com.au

CSL Limited | ABN 99 051 588 348 | 655 Elizabeth Street, Melbourne VIC 3000



CSL



Tim, patient living with Hemophilia A

2026 Full Year Results

18 August 2026

Gordon Naylor
Interim Chief Executive
Officer & Managing Director

Ken Lim
Chief Financial Officer

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, **CSL**) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (**ASX**), available at www.asx.com.au. This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", "project", "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as at the date of this release in relation to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct.

The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performance or achievements of CSL to be materially different to future results, performance or achievements expressed or implied by the statements. Readers are cautioned against reliance on forward-looking statements.

For example, fluctuations in interest and currency exchange rates, or legislative or regulatory changes affecting the pricing or reimbursement of CSL's products, including tariffs and most-favoured nation (MFN) pricing requirements, could cause actual results to differ materially. Other factors that could cause actual results to differ materially include: the success or otherwise of CSL's research and development activities; factors affecting CSL's ability to successfully market and sell new and existing products, including decisions by regulatory authorities regarding approval of CSL's products and regarding label claims; competitive developments affecting CSL's products, and trade buying patterns; factors affecting CSL's ability to collect plasma, and difficulties or delays in manufacturing; legislation or regulations affecting the manufacturing or distribution of CSL's products, market access for CSL's products, environmental protection matters, or tax; litigation or government investigations; acquisitions or divestitures; and CSL's ability to protect its patents and other intellectual property.

Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a TM or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.



CEO Overview

Gordon Naylor

**Interim CEO &
Managing Director**

FY26 a reset year

- Interim CEO appointed to accelerate CSL's strategic transformation
- Enhanced focus on commercial execution
- Operational simplification and efficiency
- Transformation program
 - Restructuring initiatives on track
 - Driving cost savings and disciplined reinvestment
- Positioned to return to sustainable growth

FY26 Performance¹


Revenue \$15.8b ↓1%

Underlying NPATA^{2,3} \$3.1b ↓2%

Underlying NPAT⁷ \$2.8b ↓3%
excluding one-off restructuring costs & impairments

Reported NPAT (Loss)³ (\$2.6b)

Cashflow from Ops \$3.5b ↓1%



Revenue¹

■	CSL Behring	(1%)
■	CSL Seqirus	(8%)
■	CSL Vifor	3%

FY26 performance

- Consistent with May 2026 update
- Reported results include one-off pre-tax restructuring costs of \$0.8b and impairment and related costs of \$7.1b
- Robust Ig demand
- Strong uptake of ANDEMBRY[®] and HEMGENIX[®]
- Growth in seasonal influenza vaccines

Strong progress on transformation initiatives

- Cost savings of \$176m realised
- Partial reinvestment in commercial and pipeline initiatives

Strong balance sheet and cash flows

- ~A\$1b buyback completed

Dividend maintained



Revenue \$11,387m ↓1%¹

Therapy	Revenue (\$m)	Change ¹
Ig	6,248	-
Albumin	1,115	(17%)
Haemophilia	1,515	(1%)
Hereditary Angioedema	884	14%
Perioperative Bleeding	834	(11%)

Commentary

- Medicare Part D impact
- Channel inventory normalised
- 2H up 7%¹ on PCP, up 4% on TP¹

- Government cost containment measures in China
- Expanded China footprint and Baheal partnership
- 2H down 5%¹ on PCP

- Strong growth in HEMGENIX® up 25%¹
- Decline in legacy FVIII portfolio

- Strong uptake of ANDEMBRY®
 - Launched in 19 markets

- KCENTRA® ongoing price pressure in US

Major Brands



AlbuRx®



Portfolio execution

- Robust underlying Ig demand
- Investments in field force in US & China
- China albumin market stabilising
 - Price declining at a slower rate
- ANDEMBRY® launch exceeded expectations
- VMX-C001 phase 3 trial commenced
- Clazakizumab
 - Phase 3 for CV events in ESKD
 - Licenced to Eli Lilly in additional indications* (\$100m upfront payment in FY26)

Operational highlights

- Renewed focus on plasma collection efficiency
 - Continued reduction in CPL
 - Closure of underperforming centres
 - A portion of the plasmapheresis fleet to transition to the latest generation Haemonetics machines in the US
- Manufacturing yield initiatives progressing
 - Planning for Horizon 2 clinical studies
- Commencement of Kankakee Ig facility

Revenue \$2,379m ↑3%¹

Therapy	Revenue (\$m)	Change ¹
Nephrology <i>Dialysis</i>	1,036	18%
Nephrology <i>Non-Dialysis</i>	330	17%
Iron	915	(16%)

Commentary

- VELPHORO® – TDAPA inclusion led to strong growth in 1H
 - 2H down 8%¹ on TP ahead of expiry of TDAPA on 31 Dec 2026

MIRCERA^a
methoxy polyethylene glycol-epoetin beta

VELPHORO[®]

Retacrit^b
epoetin alfa-cpbx

KAPRUVIA

- FILSPARI® – strong patient uptake in launch markets
- VELTASSA® growth in new markets
- TAVNEOS® declined by 60%¹ in 2H on TP

Veltassa

TAVNEOS[™]
tavacopani^c

FILSPARI[®]^d

- Increased generic competition in EU & US

ferinject[®]
ferric hexametate

Venofer
iron sucrose injection, USP

a. Licensed from F. Hoffmann-La Roche AG;

b. Licensed from Pfizer Inc.;

c. Rights to EU, UK, Japan and certain other countries licensed from ChemoCentryx, Inc., a wholly owned subsidiary of Amgen, Inc.

d. Rights to EU, AUS&NZ and certain other countries licensed from Travele Therapeutics, Inc.

Portfolio dynamics

- Significant portfolio headwinds
- Generic entrants in US market, challenging INJECTAFER®
- Continued generic competition in iron in Europe
- VELPHORO® sales impacted by pre-TDAPA roll off shipment timing
- TAVNEOS® marketing authorisation revoked

Operational highlights

- Integration with CSL Behring commercial & medical affairs
- Allocation of resources from CSL Vifor to CSL Behring

Revenue \$2,031m ↓ 8%¹

Therapy	Revenue (\$m)	Change ¹
Adjuvanted Egg	968	5%
Cell Culture	503	5%
Egg Based	107	(6%)
<i>Total Seasonal Influenza</i>	<i>1,578</i>	<i>4%</i>
In-license / Other	270	(47%)
Pandemic Reservation Fees	183	(1%)

Commentary

- Only global company to grow year over year in seasonal influenza revenue
- Success of RWE strategy for FLUCELVAX® and FLUAD®
- Successful launches in Germany and France
- Growth in US IDN and pediatric segments despite challenging US market
- Last season of standard egg-based AFLURIA®
- Non-recurring revenue relating to the avian influenza threat in FY25

Major Brands



Portfolio execution

- Differentiation strategy driving outperformance and market share gains in US & EU
- Geographic expansion
 - Successful first season in Germany and market entry in France with enhanced recommendations for FLUAD®
 - Multi-year PAHO agreement for market and volume expansion in South America
- AUJEMFLU® (aTIVc) approved in UK and positive CHMP recommendation from EMA
- End of collaboration with Arcturus Therapeutics on sa-mRNA technology platform

Operating highlights

- Operational separation complete
- Leveraging RWE strategy for FLUCELVAX®
- Enhanced recommendations achieved for FLUAD® in the Republic of Ireland, France, Italy, and Taiwan
- Tullamarine facility officially opened allowing Seqirus to focus on differentiated portfolio
- Cell-based pandemic influenza agreements expanded in Canada, New Zealand, and Australia



Financials

Ken Lim

CFO

CSL Group

Financial highlights

US\$ millions	FY25 Reported	FY26 Reported	FY26 at CC ¹	Change % ¹
Total Revenue	15,558	15,797	15,371	(1%)
Gross Profit⁴	8,443	8,454	8,269	(2%)
GP % ⁴	54.3%	53.5%	53.8%	
Sales & Marketing ⁴	(1,616)	(1,691)	(1,642)	(2%)
Operating Result⁴	6,827	6,763	6,627	(3%)
R&D ⁴	(1,359)	(1,223)	(1,181)	(13%)
G&A ⁴	(1,000)	(920)	(874)	(13%)
Net Interest Expense	(410)	(405)	(402)	(2%)
NPATA^{2,3}	3,219	3,098	3,142	(2%)
Underlying NPAT³	2,972	2,837	2,881	(3%)
Other acquisition and disposal adjustments	30	-	-	(100%)
Restructuring and Impairment ^{3,6}	-	5,416	5,391	-
NPAT (Loss)³	3,002	(2,579)	(2,510)	(184%)
Underlying NPATA ETR %	15.9%	20.8%	19.1%	
Cashflow from Ops	3,561	3,512		(1%)
Underlying NPATA EPS ³ (\$)	6.65	6.43		(3%)
DPS (\$)	2.92	2.92		-

Cashflow

- Strong cashflow

R&D

- Strong progress on restructuring initiatives
- Disciplined reinvestment

G&A

- Impact of cost management initiatives

Finance

- Leverage of 1.8 times⁵

Tax

- FY25 tax benefited from FX

Bridge to underlying performance

	FY25 Reported	FY26 Reported	FY26 @CC	Change % ¹
NPATA^{2,3}	\$3,219m	\$3,098m	\$3,142m	(2%)
Acquired intellectual property amortisation (post-tax)	(\$307m)	(\$322m)	(\$322m)	(5%)
NCI share of the above adjustments	\$60m	\$61m	\$61m	2%
Underlying NPAT to CSL shareholders⁷	\$2,972m	\$2,837m	\$2,881m	(3%)
Restructuring & Impairment expenses (post-tax)	-	(\$6,000m)	(\$5,975m)	
Other acquisition and disposal adjustments (post-tax)	\$30m	-	-	
NCI share of impairment expenses	-	\$584m	\$584m	
NPAT / NPAT (Loss) to CSL shareholders	\$3,002m	(\$2,579m)	(\$2,510m)	(184%)


Segment

Financial highlights

	CSL Behring		CSL Vifor		CSL Seqirus	
US\$ millions reported	FY26	Change % at CC ¹	FY26	Change % at CC ¹	FY26	Change % at CC ¹
Sales	11,087	(1%)	2,316	2%	1,809	(7%)
Other Revenue	300	32%	63	71%	222	(17%)
Total Revenue	11,387	(1%)	2,379	3%	2,031	(8%)
Gross Profit ⁴	5,648	(2%)	1,655	3%	1,151	(9%)
GP % ⁴	49.6%	-70bps	69.6%	+20bps	56.7%	-50bps
Sales & Marketing	(1,036)	8%	(403)	(15%)	(252)	8%
Operating Result⁴	4,612	(4%)	1,252	11%	899	(12%)
Operating Segment % ⁴	40.5%	-140bps	52.6%	+370bps	44.3%	-230bps

Strong progress on transformation initiatives

Annual pre-tax cost savings



- FY26 one-off pre-tax restructuring costs \$799m*
- FY26 cost savings delivered above target
- Majority of savings across R&D, Commercial & Medical and Operations
- Disciplined approach to reinvestment
 - ~\$30m reinvested in commercial initiatives
 - ~\$50m on VMX-C001

* Cash phasing - \$339m in FY26 and ~\$300m in FY27

Impairments

FY26 \$7.1b (1H \$1.6b, 2H \$5.5b)

Key components of non-cash impairment and related charges for 2H26


CSL VIFOR	\$4.1b	• Change in competitor dynamics • Generic competition • VELPHORO® TDAPA conclusion • TAVNEOS® marketing authorisation revoked • Goodwill
OTHER ASSETS	\$1.4b	• Primarily PPE impairments related to asset and site utilisation changes
TOTAL	\$5.5b	

Anticipated FY27 impairments ~\$200m

Notes:


1. Impairments above are pre-tax and pre-NCI – refer to **Appendix C** for further details
2. Anticipated FY27 impairments are subject to further analysis, business developments, external audit and Board approval

Capital Expenditure



- FY26 capex \$766m in line with expectations
- Investment in lg capacity at Kankakee commenced
- FY27 capex anticipated to be ~\$1b +/- \$100m

Balance Sheet



- Strong cash flow has significantly de-levered the Balance Sheet
- Sufficient capacity to support investment in growth opportunities
- Leverage within target range of 1.5x – 2.0x
- Dividend maintained
- Progression of buy-back program
 - A\$1b in FY26
 - A\$1.1b in FY27



CEO Overview

Gordon Naylor

**Interim CEO &
Managing Director**

FY27 Outlook (at FY26 FX rates)

Behring and Seqirus return to growth; Vifor headwinds

CSL Behring

- Mid-single digit revenue growth
 - Ig growth in line with market: mid-to-high single digits
 - Continued strong uptake of ANDEMBRY®
 - Consistent HEMGENIX® uptake
- Modest improvement in gross margin expected

CSL Vifor

- Revenue decline ~25%
 - Continued impact of generic competition in iron
 - VELPHORO® TDAPA conclusion
 - TAVNEOS® marketing authorisation revoked

CSL Seqirus

- Low single digit revenue growth
 - Momentum in new markets and targeted customer segments
 - Ex-US immunisation rates stabilised; US rate of decline slowing

CSL Group

- Incremental savings from transformation program
 - ~50% reinvested in growth opportunities
- Strong cash flow from operations
- Continuation of share buy-back A\$1.1b



FY27 Guidance

Revenue

In-line with FY26 @CC¹

Underlying NPAT⁷ Growth

~5% @CC^{1,3}

*FX impact estimated to be a headwind of ~\$50m if current rates remain unchanged for the remainder of the Financial Year
Anticipated FY27 impairments ~\$200m*





CSL Contacts

Michelle Rees
Investor Relations
☎ +61 410 600 745
michelle.rees@csl.com.au

Bernard Ronchi
Investor Relations
☎ +61 431 060 964
bernard.ronchi@csl.com.au

Jimmy Baker
Investor Relations
☎ +61 450 909 211
jimmy.baker@csl.com.au



Appendix

Notes

Constant Currency

(#) Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance for the Group. This is done in three parts: a) by converting the current year net profit of entities in the group that have reporting currencies other than US Dollars, at the rates that were applicable to the prior year (translation currency effect); b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior year (transaction currency effect); and c) by adjusting for current year foreign currency gains and losses. The sum of translation currency effect, transaction currency effect and foreign currency gains and losses is the amount by which reported net profit is adjusted to calculate the operational result.

Average exchange rates for major currencies for the full year ended 30 June 2026 and 2025 include: USD/EUR (0.86/0.92), USD/AUD (1.48/1.55), USD/CHF (0.79/0.87), USD/CNY (7.01/7.21) and USD/GBP (0.74/0.77).

Constant currency net (loss) / profit after tax and constant currency revenue have not been audited or reviewed in accordance with Australian Auditing Standards.

General Disclaimer Non-IFRS

There are references to IFRS (International Financial Reporting Standards) and non-IFRS financial information in this document. Non-IFRS financial measures are financial measures other than those defined or specified under any relevant accounting standard and may not be directly comparable with other companies' information. Non-IFRS financial measures are used to enhance the transparency and comparability of a financial report. Non-IFRS financial information should be considered in addition to, and is not intended to be a substitute for, IFRS financial information and measures. Non-IFRS financial measures are not subject to audit or review.

Summary NPAT (Loss) attributable to members of parent entity US\$m

Reported NPAT (Loss) ³	(\$2,579m)
-----------------------------------	------------

Currency effect	\$69m
-----------------	-------

Constant currency# NPAT (loss) after tax³	(\$2,510m)
---	-------------------

Summary underlying NPATA² attributable to members of the parent entity US\$m

Reported NPAT (Loss) ³	(\$2,579m)
-----------------------------------	------------

Amortisation of acquired intellectual property (net of tax)	\$261m
---	--------

Restructuring and impairment expenses (net of tax)	\$5,416m
--	----------

Underlying NPATA² attributable to members of the parent entity	\$3,098m
--	-----------------

Currency effect attributable to members of the parent entity	\$44m
--	-------

Underlying Constant Currency# NPATA² attributable to members of the parent entity	\$3,142m
---	-----------------

Summary Revenue US\$m

Reported revenue	\$15,797m
------------------	-----------

Currency effect	(\$426m)
-----------------	----------

Constant currency revenue#	\$15,371m
-----------------------------------	------------------

Footnotes


1. Percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance.
2. Underlying NPATA represents the statutory net (loss) / profit after tax before amortisation of acquired IP and significant non-recurring items including those related to one-off restructuring and impairments costs, business acquisitions and disposals.
3. Attributable to the shareholders of CSL Limited.
4. Underlying results have been adjusted to exclude the impacts from the amortisation of acquired IP and significant non-recurring items including those related to one-off restructuring and impairments expenses, business acquisitions and disposals.
5. Net Debt to EBITDA (based on rolling twelve months to 30 June 2026), excluding impacts from restructuring and impairments.
6. Net of tax.
7. Underlying NPAT represents the statutory net (loss)/profit after tax before one-off restructuring and impairments expenses.

Appendix A

CSL Behring Key Products

CSL Behring	Therapy Group	Sales \$m	PCP Change ¹ %
Privigen	IVIG	4,017	(1%)
Hizentra	SCIG	2,167	2%
Albumin	Albumin	1,115	(17%)
Idelvion	Haemophilia	874	1%
Kcentra	Perioperative bleeding	495	(17%)
Haegarda	HAE	431	(13%)
Humate / Haemate	Haemophilia	338	(4%)
Haemocomplettan	Perioperative bleeding	252	(2%)
Andembry	HAE	240	
Berinert	HAE	213	(17%)
Zemaira/Respreeza	Other	165	16%
Hemgenix	Haemophilia	118	25%

FY26 Revenue By Therapy Group \$m




Appendix B

CSL Vifor & CSL Seqirus Key Products


CSL Vifor	Therapy Group	Sales \$m	Change ¹ %
Ferinject/Injectafer	Iron	653	(19%)
Mircera	Nephrology: Dialysis	578	2%
Velphoro	Nephrology: Dialysis	393	51%
Veltassa	Nephrology: Non-Dialysis	157	7%
Venofer	Iron	143	(19%)
Tavneos	Nephrology: Non-Dialysis	120	(7%)
Maltofer	Iron	115	17%

CSL Seqirus	Therapy Group	Sales \$m	Change ¹ %
Fluad	Adjuvanted	968	5%
Flucelvax	Cell culture	503	5%
Afluria/Aggripal	Egg-based	107	(6%)

FY26 Revenue By Therapy Group \$m



Iron	\$915	38%
Nephrology: Dialysis	\$1,036	44%
Nephrology: Non-Dialysis	\$330	14%
Other	\$98	4%



Cell Culture	\$503	25%
Adjuvanted	\$968	48%
Egg Based	\$107	5%
In Licence	\$137	7%
Pandemic	\$183	9%
Other	\$133	6%



Appendix C

FY26 Impairment Bridge

\$m	Impairment*	Tax	Net of tax	Attributable to NCI	Attributable to CSL
CSL Vifor Goodwill	1,700				
Ferinject IP	1,548				
Venofer IP	738				
Mircera IP	301				
Velphoro IP	175				
Tavneos IP and associated expenses	166				
Other intangibles	241				
CSL Vifor Intangibles (inc. Goodwill)	4,869	(420)	4,449	(584)	3,865
sa-mRNA IP and associated expenses	590				
Other intangible assets	33				
Lengnau PPE	931				
Other PPE	499				
Other	54				
Other assets	2,107	(426)	1,681	-	1,681
Onerous contract costs	148	(33)	115	-	115
Tax losses from investment impairments	-	(853)	(853)	-	(853)
Total	7,124	(1,732)	5,392	(584)	4,808

Appendix D

NCI

CSL Vifor sales via VFMCPR by therapy area

Nephrology – Dialysis	~70%
Nephrology – Non-Dialysis	~40%
Iron	~20%

~45% of total Vifor sales

Based on FY26 sales

Appendix E

NPATA^{2,3} to NPAT Bridge

FY26 Bridge \$M	CSL	NCI	Total
Underlying NPATA ^{2,3}	3,098	238	3,336
less: IP amortisation	(307)	(72)	(379)
add: tax impact	46	10	57
IP amortisation (post tax)	(261)	(62)	(322)
Underlying NPAT⁷	2,837	176	3,014

Pre-tax \$m	Behring	Vifor	Seqirus
FY26 IP amortisation	28	351	1

FY27 Amortisation of Acquired IP \$M	CSL	NCI	Total
IP amortisation (included in COGS)	~(200)	~(50)	~(250)
add: tax impact	~30	~10	~40
IP amortisation (post tax)	~(170)	~(40)	~(210)

Movement in IP amortisation (post-tax) FY26 v FY27	~(90)	~(20)	~(110)
---	--------------	--------------	---------------

Allocation of
FY26 pre-tax
amortisation
across segments

* Acquired IP amortisation is recognised within cost of sales within the income statement.

CSL R&D Portfolio – FY26



* Ongoing Post-Marketing Studies
† Market recalls planned

■ Immunoglobulins ■ Haematology ■ Cardiovascular & Renal
■ Immunology ■ Vaccines ■ Partnered Project

Glossary

aTIVc	Adjuvanted Cell-based Trivalent Influenza Vaccine
CC	Constant Currency
CPL	Cost Per Litre
CV	Cardiovascular
ESKD	End Stage Kidney Disease
HAE	Hereditary Angioedema
IG	Immunoglobulin
IDN	Integrated Delivery Network
IP	Intellectual Property
IVIG	Intravenous Immunoglobulin
NCI	Non-Controlling Interest
NPAT	Net Profit After Tax
NPAT (Loss)	Net Loss After Tax
PCP	Prior Comparable Period
PPE	Property Plant & Equipment
RWE	Real World Evidence
sa-mRNA	Self Amplifying Messenger Ribonucleic Acid
SCIG	Subcutaneous Immunoglobulin
TDAPA	Transitional Drug Add-on Payment Adjustment
TP	Trailing Period
VFMCRP	Vifor Fresenius Medical Care Renal Pharma